Synonyms: BMF-219 | BMF219 | Compound 10 [US20200223853A1]
Compound class:
Synthetic organic
Comment: Icovamenib (BMF-219) is an orally bioavailable, irriversible (covalent) menin inhibitor (structure from [2]). In mixed lineage leukaemia gene (MLL)-rearranged leukaemias menin drives leukaemic transformation through a direct interaction with the MLL protein (a histone methyltransferase encoded by the KMT2A gene). Inhibitors of the MLL-menin interaction are being developed as a novel therapeutic class to block leukaemogenesis and induce apoptosis of leukaemic blasts as an approach for the treament of aggressive haematopoietic malignancies [2]. Menin also interacts with and regulates activity of the MYC transcription factor/oncoprotein, so menin inhibitors may also be of value in MYC-driven cancers [3].
BMF-219 is one of the menin inhibitor compounds claimed in patent US20200223853A1 (as Compound 10) [1]. |
|
Bioactivity Comments |
Anti-proliferative activity of this compound against cell lines with MLL rearrangements is provided in the claiming patent US20200223853A1 [1]. |